Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study - Scorecard - MDSpire
Advertisement
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study
Clinical Scorecard: Genetic Variants and Their Relationship to Quality of Life and Pain Perception in Participants of the UK NCRI Myeloma X Relapse (Intensive) Trial: An Exploratory Analysis
At a Glance
Category
Detail
Condition
Relapsed multiple myeloma with associated pain and quality of life impact
Key Mechanisms
Pain arises from bone marrow infiltration, bone osteolysis, treatment side effects (e.g., chemotherapy-induced peripheral neuropathy), genetic variants affecting opioid receptors and drug metabolism, and physiological modulators of pain
Target Population
Patients with relapsed multiple myeloma undergoing salvage autologous stem cell transplant or non-transplant consolidation
Care Setting
Oncology clinical trial and supportive care settings focusing on symptom management and quality of life
Key Highlights
Multiple myeloma pain is multifactorial involving tumor biology, treatment effects, and genetic factors influencing pain perception and analgesic response.
The Myeloma X trial demonstrated improved survival with salvage autologous stem cell transplant but identified increased pain and reduced quality of life in the peri-transplant period.
Genetic variants in opioid receptor genes and drug metabolism pathways may influence individual pain experience and analgesic requirements in myeloma patients.
Guideline-Based Recommendations
Diagnosis
Use validated instruments such as the Brief Pain Inventory (BPI-SF) to assess pain severity and impact.
Evaluate health-related quality of life using tools like the EORTC-QLQ-C30 including physical functioning, pain, and fatigue scales.
Management
Incorporate supportive and symptomatic care focusing on pain control throughout all disease stages.
Consider genetic factors that may affect opioid receptor function and analgesic metabolism when tailoring pain management strategies.
Monitor and manage chemotherapy-induced peripheral neuropathy as a significant contributor to pain.
Monitoring & Follow-up
Regularly assess pain and quality of life longitudinally, especially during and after salvage autologous stem cell transplant.
Monitor analgesic dosage and response in relation to patient genetic profiles where available.
Risks
Increased pain and reduced quality of life may occur in the peri-transplant period following salvage autologous stem cell transplant.
Potential for higher opioid requirements and toxic metabolite accumulation in patients with certain genetic variants.
Patient & Prescribing Data
Relapsed multiple myeloma patients enrolled in the Myeloma X trial receiving salvage autologous stem cell transplant or non-transplant consolidation
Patients receiving salvage autologous stem cell transplant experienced greater pain and treatment side effects initially but better long-term outcomes; genetic variation may influence analgesic needs and pain perception.
Clinical Best Practices
Employ comprehensive pain and quality of life assessments using validated patient-reported outcome measures.
Integrate genetic testing for opioid receptor variants and drug metabolism genes to personalize analgesic therapy when feasible.
Provide multidisciplinary supportive care addressing both disease-related and treatment-related pain components.
Anticipate and proactively manage increased pain and symptom burden in the peri-transplant period.
by John A. Snowden, Sam H. Ahmedzai, Angela Cox, David A. Cairns, A. John Ashcroft, Cathy Williams, Jamie D. Cavenagh, Anna Hockaday, Julia M. Brown, Ian W. Brock, Treen C. M. Morris, Gordon Cook
